Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the
world. A wealth of literature suggests that vitamin D and its analogs have profound effects
on immune system function and glomerular mesangial cell proliferation. However, calcitriol,
the standard form of vitamin D, carries a substantial risk of hypercalcemia. Recently,
paricalcitol (19-nor-1,25-dihydroxyvitamin D2) was approved for the treatment of secondary
hyperparathyroidism in chronic renal failure, and the incidence of hypercalcemia is much
lower than calcitriol. Therefore, the investigators plan to conduct a randomized cross-over
study to evaluate the efficacy of paricalcitol in the treatment of IgA nephropathy. Thirty
patients with biopsy-proven IgA nephropathy will be recruited. They will be randomized to
paricalcitol for 12 weeks or no treatment, followed by cross over to the other arm after a
washout period. Proteinuria, renal function, serum and urinary inflammatory markers will be
monitored. This study will explore the potential anti-proteinuric and anti-inflammatory
effects of paricalcitol in the treatment of IgA nephropathy, which has no specific treatment
at present.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese University of Hong Kong
Treatments:
Antibodies Ergocalciferols Immunoglobulin A Immunoglobulins